Tarlatamab plus durvalumab extends ES-SCLC survival: interim

Editor's Pick: Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer (New England Journal of Medicine, 2026)
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning new targeted and immune strategies in lung cancer, immunotherapy for mismatch repair-deficient colorectal cancer, and antibody-drug conjugates moving into earlier lines of therapy. Let's dive in.
This week's papers:
• Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. — New England Journal of Medicine 2026 (pubmed.ncbi.nlm.nih.gov/42929702)
• Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC. — New England Journal of Medicine 2026 (pubmed.ncbi.nlm.nih.gov/42929675)
• Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy. — New England Journal of Medicine 2026 (pubmed.ncbi.nlm.nih.gov/42929693)
• Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial. — The Lancet 2026 (pubmed.ncbi.nlm.nih.gov/42906564)
• Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial. — Annals of Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42927858)
• Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW. — Annals of Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42926106)
• 14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan. — The Lancet 2026 (pubmed.ncbi.nlm.nih.gov/42925880)
• Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC. — New England Journal of Medicine 2026 (pubmed.ncbi.nlm.nih.gov/42929694)
• Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial. — JAMA 2026 (pubmed.ncbi.nlm.nih.gov/42925007)
• Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer. — New England Journal of Medicine 2026 (pubmed.ncbi.nlm.nih.gov/42929692)
Listen at AudioScholar (audioscholar.cc/episode/esntzj8j3z)